Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c447b57ce1103219f0e4583b3ca9319a |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-565 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y301-06013 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-33 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-30 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2869 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-13 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K19-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-55 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-62 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-63 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-46 |
filingDate |
2020-10-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b428ba24a1fd49ceefae6959f24763ef http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9d1daa2735c0307640c7b5d95e176db9 |
publicationDate |
2021-01-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
JP-2021008488-A |
titleOfInvention |
Methods and Compositions for Increasing Iduronate-2-sulfatase Activity in CNS |
abstract |
PROBLEM TO BE SOLVED: To provide a method and a composition for treating a subject suffering from iduronate-2-sulfatase deficiency in CNS. SOLUTION: The method comprises systemically administering a therapeutically effective amount of a fusion antibody having isulonic acid-2-sulfatase activity to a subject, wherein the fusion antibody is (a) immunoglobulin heavy chain and isulonic acid-2. -Fusion protein containing the amino acid sequence of sulfatase, in which the amino acid sequence of isulonate-2-sulfatase is covalently linked to the carboxy terminal of the amino acid sequence of the immunoglobulin heavy chain; and (b) immunoglobulin light chain. A method in which a fusion antibody crosses the blood-brain barrier (BBB) and catalyzes the hydrolysis of the 2-sulfate group of L-iduronate-2-sulfate units of dermatane sulfate, heparan sulfate or heparin. [Selection diagram] None |
priorityDate |
2009-10-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |